External validation of a multiplex urinary protein panel for the detection of bladder cancer in a multicenter cohort

Cancer Epidemiology Biomarkers and Prevention

Volumn 23, Issue 9, 2014, Pages 1804-1812

  Chen, Li Mei ^a   Chang, Myron ^b   Dai, Yunfeng ^b   Chai, Karl X ^a   Dyrskjøt, Lars ^c   Sanchez Carbayo, Marta ^d   Szarvas, Tibor ^e   Zwarthoff, Ellen C ^f   Lokeshwar, Vinata ^g   Jeronimo, Carmen ^h,i   Parker, Alexander S ^j   Ross, Shanti ^k   Borre, Michael ^c   Ørntoft, Torben F ^c   Jaeger, Tobias ^e   Beukers, Willemien ^f   Lopez, Luis E ^g   Henrique, Rui ^h,i   Young, Paul R ^j   Urquidi, Virginia ^k,l   Goodison, Steve ^j,k,l   Rosser, Charles J ^k,l,m   more..

^a UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d Proteomics Unit   (Spain)

^e UNIVERSITY HOSPITAL ESSEN   (Germany)

^f ERASMUS MEDICAL CENTER   (Netherlands)

^g UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^h PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

ⁱ UNIVERSITY OF PORTO   (Portugal)

^j MAYO CLINIC   (United States)

^k M D ANDERSON CANCER CENTER ORLANDO   (United States)

^l Nonagen BioScience Corp   (United States)

^m UNIVERSITY OF HAWAII   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE B; INTERLEUKIN 8; PROTEIN ANG; PROTEIN APOE; PROTEIN CA9; PROTEIN SDC1; PROTEIN SERPINA1; PROTEIN SERPINE1; STROMELYSIN 2; TUMOR MARKER; UNCLASSIFIED DRUG; VASCULOTROPIN A;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER GRADING; COHORT ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MUSCLE INVASIVE BLADDER CANCER; NON MUSCLE INVASIVE BLADDER CANCER; PREDICTIVE VALUE; PROTEIN URINE LEVEL; SENSITIVITY AND SPECIFICITY; CLINICAL TRIAL; EUROPE; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PROTEINURIA; REPRODUCIBILITY; UNITED STATES; URINARY BLADDER NEOPLASMS; URINE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; COHORT STUDIES; EUROPE; HUMANS; MALE; MIDDLE AGED; PROTEINURIA; REPRODUCIBILITY OF RESULTS; UNITED STATES; URINARY BLADDER NEOPLASMS; YOUNG ADULT;

EID: 84907164391     PISSN: 10559965     EISSN: 15387755     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-14-0029     Document Type: Article

References (64)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29.
2. Jemal A, Bray F, CenterMM, Ferlay J, Ward E, FormanD. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
3. Aben KK, Kiemeney LA. Epidemiology of bladder cancer. Eur Urol 1999; 36: 660-72.
4. Hall MC, Chang SS, Dalbagni G, Pruthi RS, Seigne JD, Skinner EC, et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 2007; 178: 2314-30.
5. vanRhijn BW, van der Poel HG, van der Kwast TH. Urine markers for bladder cancer surveillance: a systematic review. Eur Urol 2005; 47: 736-48.
6. Yang N, Feng S, Shedden K, Xie X, Liu Y, Rosser CJ, et al. Urinary glycoprotein biomarker discovery for bladder cancer detection using LC/MS-MS and label-free quantification. Clin Cancer Res 2011; 17: 3349-59.
7. Kreunin P, Zhao J, Rosser C, Urquidi V, Lubman DM, Goodison S. Bladder cancer associated glycoprotein signatures revealed by urinary proteomic profiling. J Proteome Res 2007; 6: 2631-9.
8. Urquidi V, Goodison S, Cai Y, Sun Y, Rosser CJ. A candidate molecular biomarker panel for the detection of bladder cancer. Cancer Epidemiol Biomarkers Prev 2012; 21: 2149-58.
9. Rosser CJ, Liu L, Sun Y, Villicana P, McCullers M, Porvasnik S, et al. Bladder cancer-associated gene expression signatures identified by profiling of exfoliated urothelia. Cancer Epidemiol Biomarkers Prev 2009; 18: 444-53.
10. Urquidi V, Goodison S, Ross S, Chang M, Dai Y, Rosser CJ. Diagnostic potential of urinary 1-antitrypsin and apolipoprotein E in the detection of bladder cancer. J Urol 2012; 188: 2377-83.
11. Urquidi V, Kim J, Chang M, Dai Y, Rosser CJ, Goodison S. CCL18 in a multiplex urine-based assay for the detection of bladder cancer. PLoS ONE 2012; 7: e37797.
12. Urquidi V, Chang M, Dai Y, Kim J, Wolfson ED, Goodison S, et al. IL-8 as a urinary biomarker for the detection of bladder cancer. BMC Urol 2012; 12: 12.
13. Urquidi V, Goodison S, Kim J, Chang M, Dai Y, Rosser CJ. Vascular endothelial growth factor, carbonic anhydrase 9, and angiogenin as urinary biomarkers for bladder cancer detection. Urology 2012; 79: 1185.e1-6.
14. Goodison S, Chang M, Dai Y, Urquidi V, Rosser CJ. A multi-analyte assay for the non-invasive detection of bladder cancer. PLoS ONE 2012; 7: e47469.
15. Rosser CJ, Ross S, Chang M, Dai Y, Mengual L, Zhang G, et al. Multiplex protein signature for the detection of bladder cancer in voided urine samples. J Urol 2013; 190: 2257-62.
16. Fristrup N, Ulhøi BP, Birkenkamp-Demtröder K, Mansilla F, Sanchez- Carbayo M, Segersten U, et al. Cathepsin E, maspin, Plk1, and survivin are promising prognostic protein markers for progression in nonmuscle invasive bladder cancer. Am J Pathol 2012; 180: 1824-34.
17. Canesin G, Gonzalez-Peramato P, Palou J, Urrutia M, Cordón-Cardo C, Sánchez-Carbayo M. Galectin-3 expression is associated with bladder cancer progression and clinical outcome. Tumour Biol 2010; 31: 277-85.
18. Szarvas T, Jäger T, Becker M, Tschirdewahn S, Niedworok C, Kovalszky I, et al. Validation of circulating MMP-7 level as an independent prognostic marker of poor survival in urinary bladder cancer. Pathol Oncol Res 2011; 17: 325-32.
19. Zuiverloon TC, Beukers W, van der Keur KA, Nieuweboer AJ, Reinert T, Dyrskjot L, et al. Combinations of urinary biomarkers for surveillance of patients with incident nonmuscle invasive bladder cancer: the European FP7 UROMOL project. J Urol 2013; 189: 1945-51.
20. Yates TJ, Knapp J, Gosalbez M, Lokeshwar SD, Gomez CS, Benitez A, et al. C-X-C chemokine receptor 7: a functionally associated molecular marker for bladder cancer. Cancer 2013; 119: 61-71.
21. Costa VL, Henrique R, Danielsen SA, Eknaes M, Patrício P, Morais A, et al. TCF21 and PCDH17 methylation: an innovative panel of biomarkers for a simultaneous detection of urological cancers. Epigenetics 2011; 6: 1120-30.
22. Lokeshwar VB, Habuchi T, Grossman HB, Murphy WM, Hautmann SH, Hemstreet GP 3rd, et al. Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology 2005; 66: 35-63.
23. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Fam Pract 2004; 21: 4-10.
24. Reid CN, Stevenson M, Abogunrin F, Ruddock MW, Emmert-Streib F, Lamont JV, et al. Standardization of diagnostic biomarker concentrations in urine: the hematuria caveat. PLoS ONE 2012; 7: e53354.
25. Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 2002; 30: 207-10.
26. Fluss R, Faraggi D, Reiser B. Estimation of the Youden Index and its associated cutoff point. Biom J 2005; 47: 458-72.
27. Pepe MS, Feng Z, Janes H, Bossuyt PM, Potter JD. Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. J Natl Cancer Inst 2008; 100: 1432-8.
28. JochamD, Stepp H, Waidelich R. Photodynamic diagnosis in urology: state-of-the-art. Eur Urol 2008; 53: 1138-48.
29. Avritscher EB, Cooksley CD, Grossman HB, Sabichi AL, Hamblin L, Dinney CP, et al. Clinical model of lifetime cost of treating bladder cancer and associated complications. Urology 2006; 68: 549-53.
30. Lotan Y, Svatek RS, Sagalowsky AI. Should we screen for bladder cancer in a high-risk population? A cost per life-year saved analysis. Cancer 2006; 107: 982-90.
31. Svatek RS, Sagalowsky AI, Lotan Y. Economic impact of screening for bladder cancer using bladder tumor markers: a decision analysis. Urol Oncol 2006; 24: 338-43.
32. Stein M, Lubetkin D, Taub HC, Skinner WK, Haberman J, Kreutzer ER. The effects of intraurethrallidocaine anesthetic and patient anxiety on pain perception during cystoscopy. J Urol 1994; 151: 1518-21.
33. Schrag D, Hsieh LJ, Rabbani F, Bach PB, Herr H, Begg CB. Adherence to surveillance among patients with superficial bladder cancer. J Natl Cancer Inst 2003; 95: 588-97.
34. Nakamura K, Kasraeian A, Iczkowski KA, Chang M, Pendleton J, Anai S, et al. Utility of serial urinary cytology in the initial evaluation of the patient with microscopic hematuria. BMC Urol 2009; 9: 12.
35. Kumar A, Kumar R, Gupta NP. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer. Jpn J Clin Oncol 2006; 36: 172-5.
36. Raitanen MP, Aine R, Rintala E, Kallio J, Rajala P, Juusela H, et al. Differences between local and review urinary cytology in diagnosis of bladder cancer: an interobserver multicenter analysis. Eur Urol 2002; 4: 284-9.
37. Thomas L, Leyh H, Marberger M, Bombardieri E, Bassi P, Pagano F, et al. Multicenter trial of the quantitative BTA TRAK assay in the detection of bladder cancer. Clin Chem 1999; 45: 472-7.
38. Mahnert B, Tauber S, Kriegmair M, Nagel D, Holdenrieder S, Hofmann K, et al. Measurements of complement factor H-related protein (BTATRAK assay) and nuclear matrix protein (NMP22 assay)-useful diagnostic tools in the diagnosis of urinary bladder cancer? Clin ChemLab Med 2003; 41: 104-10.
39. Ellis WJ, Blumenstein BA, Ishak LM, Enfield DL. Clinical evaluation of the BTA TRAK assay and comparison to voided urine cytology and the Bard BTA test in patients with recurrent bladder tumors. The Multi Center Study Group. Urology 1997; 50: 882-7.
40. Eissa S, Swellam M, Sadek M, Mourad MS, El Ahmady O, Khalifa A. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors. J Urol 2002; 168: 465-9.
41. Ramakumar S, Bhuiyan J, Besse JA, Roberts SG, WollanPC, Blute ML, et al. Comparison of screening methods in the detection of bladder cancer. J Urol 1999; 161: 388-94.
42. Nguyen B, Cusumano PG, Deck K, Kerlin D, Garcia AA, Barone JL, et al. Comparison of molecular subtyping with BluePrint, MammaPrint, and TargetPrint to local clinical subtyping in breast cancer patients. Ann Surg Oncol 2012; 19: 3257-63.
43. Malo TL, Lipkus I, Wilson T, Han HS, Acs G, Vadaparampil ST. Treatment choices based on OncotypeDx in the breast oncology care setting. J Cancer Epidemiol 2012; 2012: 941495.
44. Crew JP, O'Brien T, Bicknell R, Fuggle S, Cranston D, Harris AL. Urinary vascular endothelial growth factor and its correlation with bladder cancer recurrence rates. J Urol 1999; 161: 799-804.
45. Eissa S, Salem AM, Zohny SF, Hegazy MG. The diagnostic efficacy of urinary TGF-b1 and VEGF in bladder cancer: comparison with voided urine cytology. Cancer Biomark 2007; 3: 275-85.
46. Sheryka E, Wheeler MA, Hausladen DA, Seaton A, Wilson C, Maxwell PJ, et al. Urinary interleukin-8 levels are elevated in subjects with transitional cell carcinoma. Urology 2003; 62: 162-6.
47. Margel D, Pevsner-Fischer M, Baniel J, Yossepowitch O, Cohen IR. Stress proteins and cytokines are urinary biomarkers for diagnosis and staging of bladder cancer. Eur Urol 2011; 59: 113-9.
48. Eissa S, Ali-Labib R, Swellam M, Bassiony M, Tash F, El-Zayat TM. Noninvasive diagnosis of bladder cancer by detection of matrix metalloproteinases (MMP-2 and MMP-9) and their inhibitor (TIMP-2) in urine. Eur Urol 2007; 52: 1388-96.
49. Roy R, Louis G, Loughlin KR, Wiederschain D, Kilroy SM, Lamb CC, et al. Tumor-specific urinary matrix metalloproteinase fingerprinting: identification of high molecular weight urinary matrix metalloproteinase species. Clin Cancer Res 2008; 14: 6610-7.
50. Hyrsl L, Zavada J, Zavadova Z, Kawaciuk I, Vesely S, Skapa P. Soluble form of carbonic anhydrase IX (CAIX) in transitional cell carcinoma of urinary tract. Neoplasma 2009; 56: 298-302.
51. Chen CL, Lin TS, Tsai CH, Wu CC, Chung T, Chien KY, et al. Identification of potential bladder cancer markers in urine by abundantprotein depletion coupled with quantitative proteomics. J Proteomics 2013; 85: 28-43.
52. Aaboe M, Marcussen N, Jensen KM, Thykjaer T, Dyrskjøt L, Orntoft TF. Gene expression profiling of noninvasive primary urothelial tumours using microarrays. Br J Cancer 2005; 93: 1182-90.
53. Holyoake A, O'Sullivan P, Pollock R, Best T, Watanabe J, Kajita Y, et al. Development of a multiplex RNA urine test for the detection and stratification of transitional cell carcinoma of the bladder. Clin Cancer Res 2008; 14: 742-9.
54. Hanke M, Kausch I, Dahmen G, Jocham D, Warnecke JM. Detailed technical analysis of urine RNA-based tumor diagnostics reveals ETS2/urokinase plasminogen activator to be a novel marker for bladder cancer. Clin Chem 2007; 53: 2070-7.
55. Mengual L, Burset M, Ribal MJ, Ars E, Marin-Aguilera M, Fernandez M, et al. Gene expression signature in urine for diagnosing and assessing aggressiveness of bladder urothelial carcinoma. Clin Cancer Res 2010; 16: 2624-33.
56. Bartoletti R, Cai T, Dal Canto M, Boddi V, Nesi G, Piazzini M. Multiplex polymerase chain reaction for microsatellite analysis of urine sediment cells: a rapid and inexpensive method for diagnosing and monitoring superficial transitional bladder cell carcinoma. J Urol 2006; 175: 2032-7.
57. Xu J, Zhu D, Sonoda S, He S, Spee C, Ryan SJ, et al. Over-expression of BMP4 inhibits experimental choroidal neovascularization by modulating VEGF and MMP-9. Angiogenesis 2012; 15: 213-27.
58. Zhang G, Miyake M, Lawton A, Goodison S, Rosser CJ. Matrix metalloproteinase-10 promotes tumor progression through regulation of angiogenic and apoptotic pathways. BMC Cancer 2014; 14: 310.
59. Tashiro Y, Nishida C, Sato-Kusubata K, Ohki-Koizumi M, Ishihara M, Sato A, et al. Inhibition of PAI-1 induces neutrophil-driven neoangiogenesis and promotes tissue regeneration via production of angiocrine factors in mice. Blood 2012; 119: 6382-93.
60. Folkman J. Angiogenesis in cancer, vascular, rheumatoid, and other diseases. Nat Med 1995; 1: 27-31.
61. Folkman J, Klagsbrun M. Angiogenic factors. Science 1987; 235: 442-7.
62. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-64.
63. Blood CH, Zetter BR. Tumor interactions with the vasculature: angiogenesis and tumor metastasis. Biochem Biophys Acta 1990; 1032: 89-118.
64. Rosser CJ, Chang M, Dai Y, Ross S, Mengual L, Alcaraz A, et al. Urinary protein biomarker panel for the detection of recurrent bladder cancer. Cancer Epidemiol Biomarkers Prev 2014; 23: 1340-5.